Medtronic plc. stocks have been trading up by 5.01 percent after upbeat earnings and guidance boosted investor confidence.
Click Here for a Millionaire's POV on Trading MDT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For MDT Traders
- Medtronic plans to acquire SPR Therapeutics for about $650M in cash to add FDA-cleared temporary peripheral nerve stimulation tech and broaden minimally invasive, non-opioid chronic pain options.
- Needham expects Medtronic to beat fiscal Q4 revenue and EPS estimates, backing a Buy rating and $120 price target on MDT.
- Goldman Sachs restarted coverage on Medtronic with a Neutral rating and $84 target, highlighting a roughly 10% valuation discount to large-cap medtech peers.
- MDT is set to report earnings before tomorrow’s open, with Wall Street looking for $1.55 in EPS.
- Shares of Medtronic slipped about 1% on the roughly $650M SPR Therapeutics acquisition amid a soft healthcare tape.
Live Update At 10:02:53 EDT: On Wednesday, June 03, 2026 Medtronic plc. stock [NYSE: MDT] is trending up by 5.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Right now MDT is trading in the high-$70s, with the latest close around $77.45 after a bounce from the low-$70s earlier in the week. That move from roughly $73.75 to $77.45 in a single day tells traders money is stepping back in ahead of earnings and the SPR Therapeutics news. The multi-week chart shows MDT stuck in a broad $73–$79 range, a classic consolidation zone before a bigger trend decides.
Under the hood, Medtronic is not a story stock. It is a $33.5B revenue machine with a fat 64.9% gross margin and about 17.7% EBIT margin. That kind of profitability gives MDT real room to fund deals like SPR and still throw off cash. Free cash flow last quarter was about $2.3B, far above the $444M in capital spending, which means Medtronic can fund growth and still support a roughly 3.9% dividend yield.
More Breaking News
- MongoDB Stock Jumps As Q2 Guidance, AI Demand Impress Wall Street
- Sidus Space (SIDU) Jumps As Index Catalyst And Defense Story Build
- Nokia Stock Extends Rally As AI And Analyst Upgrades Drive NOK Momentum
- LASE Stock Surges As DefenseTech Wins Key U.S. Army Traction
Leverage looks manageable: total debt to equity at 0.57 and interest coverage of 13.1. With a P/E near 20.7 and price-to-sales around 2.7, MDT trades cheaper than many large-cap medtech names, which matches Goldman’s “10% discount” comment. For traders, this setup means the earnings print and guidance are likely to be the spark that pushes MDT out of its range.
Why Traders Are Watching MDT Into Earnings
MDT is lining up several catalysts at once, and that’s exactly when active traders should pay attention. The headline move is Medtronic’s plan to buy SPR Therapeutics for about $650M in cash. On the surface, the stock dipping around 1% on the news looks like classic “pay now, worry later” reaction. The Street is digesting deal cost and timing while healthcare as a whole trades soft.
But dig into the story and you see why this matters. SPR brings FDA-cleared, temporary peripheral nerve stimulation tech into MDT’s neuromodulation toolbox. In plain English, Medtronic is paying up to own minimally invasive, non-opioid pain solutions earlier in the treatment pathway. That fits right into the global pivot away from opioids and into device-based pain control. Long term, that kind of positioning can support higher growth and stickier customer relationships.
Analysts are lining up on both sides of the tape. Needham is firmly bullish, expecting Medtronic to beat fiscal Q4 revenue and EPS, backed by a fresh product cycle, conservative prior guidance, and possible restructuring to boost efficiency. They stick a $120 price target on MDT and talk about accelerating organic growth into FY27.
Goldman Sachs, by contrast, comes in with a Neutral rating and an $84 target. They see MDT trading at about a 10% discount to big medtech peers, but they want more proof that revenue and earnings growth will sustain. That split—Needham aggressive, Goldman cautious—sets up a real battleground heading into tomorrow’s earnings, where consensus EPS sits at $1.55. Any beat-and-raise scenario could squeeze shorts and chase momentum traders into MDT; a miss or weak guide and the range could break to the downside instead.
Conclusion
For active traders, MDT is not a meme rocket, it is a slow, heavy ship turning into a potentially better current. The SPR Therapeutics acquisition shows Medtronic is serious about owning the non-opioid pain management lane, right where regulators and patients want the industry to go. That kind of strategic fit tends to matter more over years than days, even if the stock wobbles 1% on the headline.
At the same time, the numbers back up why Wall Street is watching. MDT throws off strong free cash flow, carries moderate leverage, and earns solid returns on capital. The valuation is not screamingly cheap, but it is discounted to peers, which gives traders a defined risk-reward framework around earnings. If Needham’s call on a Q4 beat and steady FY27 guidance proves right, MDT has room to grind higher toward their $120 target over time. If Goldman’s caution about growth wins out, the stock may stay stuck in the $70s band until Medtronic proves otherwise.
The key for short-term traders is to treat MDT like any catalyst setup: plan your entries around levels, use the earnings print and conference call as your trigger, and be ruthless with risk. As Tim Sykes likes to say, “The pattern is only part of the trade — the real edge is in your discipline and how fast you cut losses when the story changes.” That mindset lines up closely with the risk-first approach many modern trading educators emphasize; as Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” MDT is giving the market a clear story right now; it’s on traders to manage the trade.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.